http://orcid.org/0000-0002-9999-4003
References
- Hernandez AV , Thota P , Pellegrino D , et al . A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med. 2016;18:1–10.
- Liberati A , Altman DG , Tetzlaff J , et al . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;6: e1–e34.10.1016/j.jclinepi.2009.06.006
- NIH National Heart, Lung and Blood Institute . Study quality assessment tools [cited 2017, March 30]. Available from: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools.
- Higgins JPT , Green S , editors. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. [cited 2017 Mar 30]. Available from: http://handbook.cochrane.org.
- Torre D , Casari S , Speranza F , et al . Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998;42(6):1346–1349.
- Beraud G , Pierre-Francois S , Foltzer A , et al . Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg [Internet]. 2009;80(4):583–7. 0
- Duval X , Pajot O , Le Moing V , et al . Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS. 2004; 18: 1342–1344.10.1097/00002030-200406180-00016
- Chaddha DS , Kalra SP , Singh AP , et al . Toxoplasmic Encephalitis in acquired immunodeficiency syndrome. J Assoc Physicians India. 1999;47:680–684.
- Smadja D , Fournerie P , Cabre P , et al . Efficacy and tolerance of cotrimoxazole for the treatment of toxoplasmic encephalitis in AIDS patients. Presse Med. 1998;27(26):1315–1320.
- Torre D , Speranza F , Marteganie R , Zeroli C , Banfi M , Airoldi M . A retrospective study of treatment of cerebral Toxoplasmosis in AIDS patients with Trimethoprim-sulphamethoxazole. J Infect. 1998;37:15–18.10.1016/S0163-4453(98)90217-1
- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents . Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [cited 2017, April 20]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
- European AIDS Clinical Society . Guidelines. Version 8.2, 2017. [cited 2017, April 20]. Available from: http://www.eacsociety.org/files/guidelines_8.2-english.pdf.
- Nelson M , Dockrell D , Edwards S , et al . British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(Suppl 2):1–5.10.1111/hiv.2011.12.issue-s2
- Connolly MP , Goodwin E , Schey C , et al . Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis. Pathog Glob Heal. 2017;111:31–44.10.1080/20477724.2016.1273597